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ABSTRACT
Objective: The aim of this study was to assess the efficacy of lornoxicam (LNX) in the treatment of acute migraine
attacks. Material and Methods: This prospective, randomized, double-blind, placebo-controlled trial was conducted
administering either LNX or placebo to patients who were diagnosed with migraine without aura according to the
International Headache Society (the year 2004) criteria between 2010 and 2012 Results: Of 44 patients with 120
migraine attacks, 38 were female and rest were males. Mean age was 37.75 ± 9.28 years. Patients recorded using
LNX in 87 migraine attacks and placebo in 33 migraine attacks, respectively. Pain intensity scores of the patients were
found similar between LNX and placebo groups, statistically. Conclusion: Although oral LNX was found to have efficacy
similar to placebo statistically in the treatment of acute migraine attacks, further studies are needed to evaluate
appropriately the efficacy of LNX for treatment of acute migraine attacks.
Key Words: Lornoxicam, migraine, acute attack, treatment efficacy
INTRODUCTION

Although the central effects of NSAIDs are not exactly
known, three mechanisms are mainly emphasized.
These are the inhibition of central nervous system
prostaglandin synthesis by NSAIDs, the increasing of
CNS catecholamine and serotonin cycle, and the
inhibition of serotonin release during pain stimulus. (6)
Lornoxicam (LNX) (6-chloro-4-hydroxy 2-methyl
N-pyridyl 2H-thienol (2, 3 e) 1, 2-thiazine
2-karbaksamid 1, 1-dioxide), is a NSAID drug in
non-selective, oxicam group according to former
classification. LNX has potent anti-inflammatory and
analgesic effects similar to other oxicams but unlike
them it has a shorter half life (3-5 hours). Both oral and
parenteral preparations are used. LNX has a better
tolerability profile compared with other oxicam drugs
because of shorter half life. (7) Clinical trials suggest LNX
as an effective drug in the treatment of post-operative
and joint pains. The aim of this study was to assess the
efficacy of LNX in treatment of headaches due to acute
migraine attacks.

Migraine is a common cause of headache. Prevalence
of migraine is reported to be 11% in the adult
population in the studies from western countries. (1) The
study, which was conducted by Turkish headache
epidemiology study group reported the incidence of
migraine to be 16.4% between 15-65 years old. (2) It is
seen three times more in women than men, and it often
occurs between the ages of 25 to 55 years. (3, 4)
Migraine treatments are generally based on two major
groups, including non-pharmacological and pharmacological methods. Pharmacological treatment is divided
into two groups; prophylactic and acute attack
treatment.(5) Acute migraine attacks should be managed
rapidly and effectively. Therapy is considered to be
successful when there is decrease in the frequency and
severity of attacks.(5) Acute attack treatment should be
tailored to the patients systemic disease and symptoms
as well as the severity, duration and frequency of the
attacks. In mild and moderate attacks, non-specific
therapy non-steroidal anti-inflammatory drugs (NSAIDs)
alone or in combination with either caffeine or codeine
may be used. Moderate and severe attacks which
cannot be prevented with nonspecific migraine drugs
are managed with specific drugs such as triptans or
ergot derivatives.(5)
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MATERIAL AND METHODS
This is a prospective, randomized, double-blind,
placebo-controlled study conducted by department of
clinical of algology, school of medicine Istanbul
University and department of neurology, Ministry of
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Health Dr. Sadi Konuk Research and Training Hospital
between January 2010 and December 2012. Inclusion
criteria was:
-

improvement; 1= a little, 2= some, 3= a lot, 4=
complete, and worsening; -1= a litte, -2= some, -3=
a lot, -4= complete) after the administration of drug at
15 th, 30 th, 60 th, 90 th minutes and at 2 nd, 3 th,
6 th, 12 th, 24 th hours. Evaluation of patient
satisfaction was assessed at the end of the 24-h period
(1= satisfied, 2= unsatisfied). (8)

age between 18 and 65 years,
being diagnosed with migraine without aura
according to the International Headache
Society criteria (the year 2004),
having experience of first headache attack
before 50 years of age,
having moderate to severe migraine attacks
with frequency less than 4 times per month.

A Statistical Analysis
Age was expressed as mean ±standard deviation.
Changes in headache severity were assessed by
Mann-Whitney U test in the pre-treatment period and
after the treatment at 15th, 30th, 60th, 90th minutes
and 2nd, 3th, 6th, 12th, 24th hours. Characteristics of
patient and placebo groups and satisfaction with the
treatment between placebo and treatment group was
assessed by Chi-square test. Statistical significance
was determined at p <0.05.

This study was approved by ethics committee that was
established in the School of Medicine, Istanbul
University. Randomization table has been used for
randomization of the patients. Diagnosis of migraine of
the included patients was done by a neurology
physician. Patients’ migraine attacks were recorded to
assess the effectiveness of LNX. After being informed
about the study, all volunteers were asked to sign the
"informed
consent
form".
Patients’
physical
examinations, pulse rates and blood pressure of
patients as well as medical history regarding usage of
drug or non-drug medications and simultaneous
systemic diseases were recorded during all visits.
Patients who were pregnant, nursing and planning to be
pregnant during the study, not informed about
treatment sufficiently, used different treatment for
migraine attacks, and who quitted the follow-up were
excluded from the study. Patients received two different
blisters containing either placebo or the study drug (8
mg LNX) for two migraine attacks during first and
second visits. The 3rd visit was arranged at the end of
the fourth week or within five days after second attack
and the 4th visit was arranged at the end of the eighth
week or within five days after third attack. They were
allowed to use maximum two tablets in a day. If
headache persisted despite the use of the two tablets
given for the study, they were permitted to use
eletriptan 40 mg as a subsidiary medicine at least an
hour after the second tablet. Patients were inquired
which blister they had taken if they had headache
attack and whether they had taken one more tablet
from blisters when headache persisted for three hours.
Migraine attacks of patients which were not recorded
during follow up were not evaluated. Pain intensity
score was rated from 0 to 3 points (0= none, 1= mild,
2= moderate, 3= severe) in the survey. Headache
severity was evaluated with a questionnaire performed
before taking the drug at 0.min and at 15th, 30th,
60th, 90th minutes and at 2nd, 3th, 6th, 12th, 24th
hours after the administration of drug. Pain relief was
assessed with a rating system of 5 points (0= none,
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Table 1: Demographic characteristics of the study
participants.
Female/Male
Age (years;
mean ± SD)
Illiterate
Elementary
School
High School
University

Placebo (n=14)
11/3
37.9 ± 10.1

LNX (n=30)
27/3
37.5 ± 8.4

2
10

1
16

2

4
9

P
0.364
0.902

0.902

RESULTS
During the study period, 6 of 50 patients were excluded
from the study due to excluding criteria. Of 44 patients
whose 120 migraine attacks were evaluated, 38 were
females. Mean age 37.75 ± 9.28 years.
Characteristics of patients have been shown in Table 1.
There was no comorbidity in both patient and placebo
groups. During the study period, LNX was used in the
87 attacks, placebo was used in the 33 attacks. The
number of headache attacks in which placebo and LNX
were used is given in Table 2.
Evaluation of patients’ pain intensity scores
The severity of the headache was assessed individually
after administration of the first dose at the beginning,
15th, 30th, 60th, 90th minutes and the 2nd, 3th, 6th,
12th, 24th hours in both groups. There was not found
difference between pain intensity scores which were
surveyed after LNX and placebo treatments, statistically
(Table 3).
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Evaluation of patients’ pain relief scores
The pain relief was assessed individually after
administration of the first dose at 15th, 30th, 60th,
90th minutes and the 2nd, 3th, 6th, 12th, 24th hours
in both groups. There was not found any difference
between pain intensity scores which were surveyed after
LNX and placebo treatments, statistically (Table 4).

treatment of acute migraine, but epigastric pain was
found significantly higher in the naproxen sodium
group. (11) Ravishankar and colleagues evaluated the
efficacy of sublingual piroxicam in patients suffering
from migraine without aura. In their study, either
piroxicam 40 mg or placebo was administered
randomly and double-blind to 60 patients who were
suffering from two to 16 migraine attacks per month
without aura at age 18-50 years. (12) The severity of the
pain was evaluated using the visual analogue scale
(VAS). This study described the decrease in pain
intensity at 15 min and even 24 hours after sublingual
piroxicam administration. This decrease was
statistically significant compared to placebo (12)
Ravishankar and his colleagues administered placebo
and the drug in different patient groups, whereas drug
and placebo were administered to the same group of
patients in our study. The small population size and
administration of both the drug and placebo into a
group of patients are likely to be related to this
insignificance. Although mean age and the number of
migraine attacks in our study were similar to
Ravinshankar’s study, sublingual form is likely to cause
to different results compared to oral form as well. Since
the administration of piroxicam sublingually reaches an
effective blood plasma concentration without being
exposed to the first-pass elimination in the liver. The
side - effect did not develop in our study. In a study
comparing of LNX with intravenous morphine in the
treatment of post operative pain, LNX was found to
provide similar analgesic effect with a lower incidence
of adverse events. (10) Adverse effects, such as nausea,
vomiting, gastritis, heartburn, and diarrhea were
reported to develop less with a sublingual form of LNX
than naproxen sodium in the study of Aabakken et al. (9)
In a study performed on healthy volunteers, it has been
verified that less gastro-duodenal injury developed with
LNX (16 mg / day) compared to naproxen sodium
(1000 mg / day). (9) The limitations of our study are
small population size, administration of both drug and
placebo in some cases, usage of only oral form of LNX.
Intravenous form of LNX should be evaluated in terms of
efficacy and side-effects compared with oral forms of
LNX with a randomized-controlled study for treatment of
acute migraine attacks. As a result, although oral LNX
was found to have efficacy similar to placebo
statistically in the treatment of acute migraine attacks,
further studies are needed, including two different
groups, two forms and different dosages of LNX to
evaluate appropriately the efficacy of LNX for treatment
of acute migraine attacks.

Evaluation of patients’ satisfaction scores
Patients’ satisfaction scores were insignificant between
LNX and placebo treatments, statistically (Table 5).
Evaluation of drug associated side-effects
No adverse reactions were with both placebo treatment
and LNX treatment.
Table 2: Distribution of the number of migraine attacks
in which LNX and placebo treatments were given
The number
of migraine
attacks
1
2
3
4
Total

Placebo
n
%

LNX
n

%

13
8
5
7
33

29
20
26
12
87

33.3
23
29.9
13.8
100

39.4
24.2
15.2
21.2
100

p

0.360

DISCUSSION
LNX has been evaluated for the first time in terms of its
efficacy and side-effects, due to the fact that there has
been no study about it in the treatment of acute
migraine attacks. In context with that although NSAIDs
were presented to be effective in the treatment of acute
migraine attacks, serum level concentration of LNX
should be measured after oral use to evaluate the
efficacy appropriately. (5) Since oral usage of LNX cannot
reach therapeutic blood concentration rapidly and
sufficiently despite its short and rapid time of action,
because of first-pass elimination. Also a parenteral form
of LNX may be evaluated or compared with oral form to
reveal its effectiveness and whether the administration
route is important or not. Despite studies showing the
effectiveness of oral administration of LNX’ are
associated with pains other than migraine it is
important to ensure early, rapid and effective plasma
concentration in pains related to migraine. (9, 10) NSAIDs
in the oxicam groups were reported to be effective for
acute migraine attacks. In a study conducted by CY et
al the effectiveness of celecoxib and naproxen sodium
in the treatment of acute migraine was investigated.
Both drugs were found to be equally effective in the
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Table 3: Evaluation of patients’ pain intensity scores after LNX and placebo treatments
Post-treatment
Pain
Beginning
intensity n (%)
score
Placebo 0
Group 1
4(12.1)
2
16(48.5)
3
13(39.4)
LNX
0
Group 1
13(14.9)
2
44(50.6)
3
30(34.5)

15-min
n (%)

30-min
n (%)

60-min
n (%)

90-min
n (%)

2-h
n (%)

3-h
n (%)

6-h
n (%)

12- h
n (%)

24-h
n (%)

5(15.6)
17(53.1)
10(31.3)
12(14.5)
38(45.8)
33(39.7)

1(3.1)
7(21.9)
16(50)
8(25)
2(2.4)
17(20.5)
32(38.5)
32(38.6)

2(6.3)
9(28.1)
13(40.6)
8(25)
8(10.1)
19(24.1)
29(36.7)
23(29.1)

3(10.7)
7(25)
11(39.3)
7(25)
4(6)
21(31.8)
23(34.9)
18(27.3)

2(6.7)
5(16.7)
12(40)
11(36.6)
7(9.3)
20(26.7)
26(34.7)
22(29.3)

2(8.3)
8(33.3)
8(33.3)
6(25.1)
13(22.1)
14(23.7)
18(30.5)
14(23.7)

3(37.5)
3(37.5)
1(12.5)
1(12.5)
14(42.4)
6(18.2)
9(27.3)
4(12.1)

2(33.3)
3(50)
1(16.7)
15(53.6)
8(28.6)
2(7.1)
3(10.7)

3(50)
3(50)
13(52)
6(24)
2(8)
4(16)

3h
n (%)
6(25)
5(20.8)
10(41.7)
3(12.5)
5(8.5)
11(18.6)
12(20.3)
20(33.9)
10(17)
1(1.7)
0.967

6h
n (%)
1(12.5)
1(12.5)
5(62.5)
1(12.5)
6(18.2)
9(27.3)
6(18.2)
9(27.3)
1(3)
2(6)
0.961

12 h
n (%)
3(50)
2(33.3)
1(16.7)
6(21.4)
11(39.3)
6(21.4)
3(10.7)
2(7.2)
0.522

24 h
n (%)
1(16.7)
2(33.3)
3(50)
6(24)
9(36)
4(16)
4(16)
2(8)
1

Table 4: The pain relief scores of the cases after LNX and placebo treatments
Post-treatment
Pain relief
score
Placebo 4
Treatment 3
2
1
0
-1
-2
-3
-4
LNX
4
Treatment 3
2
1
0
-1
-2
-3
-4
p value

15 min
n (%)
1(3.1)
4(12.5)
25(78.1)
2(6.3)
1(1.2)
5(6)
66(79.5)
11(13.3)
0.106

30 min
n (%)
1(3.1)
2(6.3)
5(15.6)
22(68.7)
2(6.3)
4(4.8)
11(13.3)
54(65)
13(15.7)
1(1.2)
0.135

60 min
n (%)
4(12.5)
8(25)
17(53.1)
3(9.4)
2(2.5)
6(7.6)
23(29.1)
36(45.6)
11(13.9)
1(1.3)
0.793

90 min
n (%)
5(17.9)
8(28.5)
12(42.9)
3(10.7)
2(3)
5(7.6)
21(31.8)
27(40.9)
10(15.2)
1(1.5)
0.466

2h
n (%)
3(10)
9(30)
12(40)
5(16.7)
1(3.3)
2(2.7)
9(12)
18(24)
33(44)
11(14.6)
2(2.7)
0.811

Table 5: Patients’ satisfaction scores
Placebo
n
Satisﬁed
18
Unsatisﬁed 15
Total
33

%
54.5
45.5
100

LNX
n
48
39
87

%
55.2
44.8
100
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